Trial Profile
An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2016
Price :
$35
*
At a glance
- Drugs Reslizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Ception Therapeutics
- 23 Feb 2010 Status changed from recruiting to completed based on Cephalon/Ception Therapeutics media release.
- 23 Feb 2010 Results reported in a Cephalon/Ception Therapeutics media release.
- 11 Sep 2009 Additional lead trial investigator (Fahrenholz JM) added as reported by Vanderbilt University Institutional Review Board.